RecruitingPhase 3NCT06855498
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Sponsor
Incyte Corporation
Enrollment
600 participants
Start Date
Feb 28, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Ability to comprehend and willingness to sign a written ICF for the study.
- Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.
- Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
- Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
- Willingness to avoid pregnancy or fathering children as defined in the protocol.
- Willingness and ability to comply with the study Protocol and procedures.
Exclusion Criteria10
- Had been permanently discontinued from study treatment during the parent study.
- Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.
- Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:
- Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
- Live, attenuated vaccine.
- Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.
- Women who are pregnant (or who are considering pregnancy) or breastfeeding.
- Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class.
- Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
- Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGpovorcitinib
Study drug will be taken orally as defined by the protocol.
Locations(330)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06855498
Related Trials
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
NCT0728764433 locations
A Study With CIT-013 in HS Patients
NCT0699323324 locations
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT0721397327 locations
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
NCT0699361056 locations
The Safety and Efficacy of Roflumilast Foam in HS
NCT072632301 location